Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms

Kaushik, Neha; Borkar, Shweta; Nandanwar, Sondavid K.; Panda, Pritam Kumar; Choi, Eun Ha; Kaushik, Nagendra Kumar

doi:10.1186/s12951-022-01364-2

Cited by 80 publications

(28 citation statements)

References 202 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The poor lymphatic drainage of tumours (part of a phenomenon known as the EPR effect) could theoretically offer an advantage of nanoformulations over conventional ones although due to its complicated nature of EPR, this needs to be validated in these studies[ 47 , 48 ]. At the same time, further considerations are constantly being applied for future applications as the concept of smart nanoplatforms that will be triggered only upon an external stimulus[ 49 - 51 ].…”

Section: Types Of Cancer Nanomedicinesmentioning

confidence: 99%

Nanomedicine approaches for treatment of hematologic and oncologic malignancies

Nteli¹,

Bajwa²,

Politakis³

et al. 2022

WJCO

View full text Add to dashboard Cite

Cancer is a leading cause of death worldwide. Nowadays, the therapies are inadequate and spur demand for improved technologies. Rapid growth in nanotechnology and novel nanomedicine products represents an opportunity to achieve sophisticated targeting strategies and multi-functionality. Nanomedicine is increasingly used to develop new cancer diagnosis and treatment methods since this technology can modulate the biodistribution and the target site accumulation of chemotherapeutic drugs, thereby reducing their toxicity. Cancer nanotechnology and cancer immunotherapy are two parallel themes that have emerged over the last few decades while searching for a cure for cancer. Immunotherapy is revolutionizing cancer treatment, as it can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. A deeper understanding of the human immune system allows the establishment of combination regimens in which immunotherapy is combined with other treatment modalities (as in the case of the nanodrug Ferumoxytol). Furthermore, the combination of gene therapy approaches with nanotechnology that aims to silence or express cancer-relevant genes via one-time treatment is gradually progressing from bench to bedside. The most common example includes lipid-based nanoparticles that target VEGF-Α and KRAS pathways. This review focuses on nanoparticle-based platforms utilized in recent advances aiming to increase the efficacy of currently available cancer therapies. The insights provided and the evidence obtained in this paper indicate a bright future ahead for immuno-oncology applications of engineering nanomedicines.

show abstract

Section: Types Of Cancer Nanomedicinesmentioning

confidence: 99%

Nanomedicine approaches for treatment of hematologic and oncologic malignancies

Nteli¹,

Bajwa²,

Politakis³

et al. 2022

WJCO

View full text Add to dashboard Cite

show abstract

“…Enhanced permeability and retention effect facilitate the targeting of small molecules of nanosize and higher deposition of drug in cancer cells compared with the normal cells. Drug targeting involves the conjugate of chemotherapeutic-loaded nanocarrier with molecules that bind to the target (tumor) cell receptors [23][24][25][26]. Liposomes are thought to be a biocompatible vesicular structure with properties similar to biological membranes.…”

Section: Introductionmentioning

confidence: 99%

Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach

et al. 2022

View full text Add to dashboard Cite

In the current study, lipid-polymer hybrid nanoparticles (LPHNPs) fabricated with lipoid-90H and chitosan, sunitinib malate (SM), an anticancer drug was loaded using lecithin as a stabilizer by employing emulsion solvent evaporation technique. Four formulations (SLPN1–SLPN4) were developed by varying the concentration of chitosan polymer. Based on particle characterization, SLPN4 was optimized with size (439 ± 5.8 nm), PDI (0.269), ZP (+34 ± 5.3 mV), and EE (83.03 ± 4.9%). Further, the optimized formulation was characterized by FTIR, DSC, XRD, SEM, and in vitro release studies. In-vitro release of the drug from SPN4 was found to be 84.11 ± 2.54% as compared with pure drug SM 24.13 ± 2.67%; in 48 h, release kinetics followed the Korsmeyer–Peppas model with Fickian release mechanism. The SLPN4 exhibited a potent cytotoxicity against MCF-7 breast cancer, as evident by caspase 3, 9, and p53 activities. According to the findings, SM-loaded LPHNPs might be a promising therapy option for breast cancer.

show abstract

“…Nanomaterial has a small volume, large surface area ( Rai et al, 2021 ), high permeability, can be effectively combined with a variety of biological materials to improve their biocompatibility, and can effectively control drug release ( Chen et al, 2016 ). Therefore, a nano-drug delivery system (NDDS) can protect encapsulated drugs from blood circulation degradation, target drug delivery, reduce systemic toxicity, improve drug solubility, and improve drug pharmacokinetics and therapeutic efficacy ( Kaushik et al, 2022 ). NDDS works best in areas where many limitations exist with molecular targeted therapy, and a need exists to push treatment boundaries for PC ( Kokkinos et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis

et al. 2022

View full text Add to dashboard Cite

Background: Nano drug delivery system (NDDS) can significantly improve the delivery and efficacy of drugs against pancreatic cancer (PC) in many ways. The purpose of this study is to explore the related research fields of NDDS for PC from the perspective of bibliometrics.Methods: Articles and reviews on NDDS for PC published between 2003 and 2022 were obtained from the Web of Science Core Collection. CiteSpace, VOSviewer, R-bibliometrix, and Microsoft Excel were comprehensively used for bibliometric and visual analysis.Results: A total of 1329 papers on NDDS for PC were included. The number of papers showed an upward trend over the past 20 years. The United States contributed the most papers, followed by China, and India. Also, the United States had the highest number of total citations and H-index. The institution with the most papers was Chinese Acad Sci, which was also the most important in international institutional cooperation. Professors Couvreur P and Kazuoka K made great achievements in this field. JOURNAL OF CONTROLLED RELEASE published the most papers and was cited the most. The topics related to the tumor microenvironment such as “tumor microenvironment”, “tumor penetration”, “hypoxia”, “exosome”, and “autophagy”, PC treatment-related topics such as “immunotherapy”, “combination therapy”, “alternating magnetic field/magnetic hyperthermia”, and “ultrasound”, and gene therapy dominated by “siRNA” and “miRNA” were the research hotspots in the field of NDDS for PC.Conclusion: This study systematically uncovered a holistic picture of the performance of NDDS for PC-related literature over the past 20 years. We provided scholars to understand key information in this field with the perspective of bibliometrics, which we believe may greatly facilitate future research in this field.

show abstract

Nanocarrier cancer therapeutics with functional stimuli-responsive mechanisms

Cited by 80 publications

References 202 publications

Nanomedicine approaches for treatment of hematologic and oncologic malignancies

Nanomedicine approaches for treatment of hematologic and oncologic malignancies

Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach

Nano-drug delivery system for pancreatic cancer: A visualization and bibliometric analysis

Contact Info

Product

Resources

About